xAI Co-founder Challenges OpenAI: Achieving Multiple Leading Advantages with a Smaller Team
According to Jinse Finance, xAI co-founder Yuhuai Wu posted on the X platform early this morning, stating: "Seeing the release of GPT-5, I feel extremely proud of xAI. With a smaller team, we are ahead in many aspects. Grok4 is the world's first unified model and has outperformed GPT-5 in benchmarks such as ARC-AGI." He believes that OpenAI is a respectable competitor and still leads in many areas. "But we are moving fast and remain relentless. We will be sharing many new models in the coming weeks!" Shortly after, Musk reposted and commented, "Well done." (Jin10)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
